Literature DB >> 28476846

Simplified Comorbidity Score and Eastern Cooperative Oncology Group Performance Score Predicts Survival in Patients Receiving Organ-preserving Treatment for Bladder Cancer.

Lisa Manig1, Lukas Käsmann1, Stefan Janssen1, Steven E Schild2, Dirk Rades3.   

Abstract

BACKGROUND/AIM: This study investigated three comorbidity scales and the Eastern Cooperative Oncology Group performance score (ECOG-PS) for survival in patients receiving local irradiation for bladder cancer. PATIENTS AND METHODS: Sixty-four patients receiving organ-preserving radio-chemotherapy or radiotherapy for urinary bladder cancer were retrospectively evaluated. Charlson Comorbidity Index (CCI), Simplified Comorbidity Score (SCS), Age-Adjusted Charlson Comorbidity Index (AAC) and ECOG-PS were analyzed for associations with survival.
RESULTS: Patients with a SCS of 0-7 points had a significantly better survival than those with 8-18 points (p=0.018). Five-year survival rates were 64% and 32%, respectively. Patients with ECOG-PS of 0-1 had a significantly better 5-year survival than patients with ECOG-PS of 2-3 (64% vs. 0%, p<0.001). For CCI (p=0.16) and AAC (p=0.49), a significant association with survival was not observed.
CONCLUSION: SCS and ECOG-PS were significantly associated with survival in patients irradiated for bladder cancer and can help estimate the prognoses of these patients. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Comorbidity scales; bladder cancer; performance status; radiotherapy; survival prognoses

Mesh:

Year:  2017        PMID: 28476846     DOI: 10.21873/anticanres.11618

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Comparison of Population-Based Observational Studies With Randomized Trials in Oncology.

Authors:  Payal D Soni; Holly E Hartman; Robert T Dess; Ahmed Abugharib; Steven G Allen; Felix Y Feng; Anthony L Zietman; Reshma Jagsi; Matthew J Schipper; Daniel E Spratt
Journal:  J Clin Oncol       Date:  2019-03-21       Impact factor: 44.544

2.  Stereotactic body radiation therapy for empirically treated hypermetabolic lung lesions: a single-institutional experience identifying the Charlson score as a key prognostic factor.

Authors:  Roman O Kowalchuk; Michael R Waters; Sujith Baliga; K Martin Richardson; Kelly M Spencer; James M Larner; Charles R Kersh
Journal:  Transl Lung Cancer Res       Date:  2020-10

3.  Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors.

Authors:  Jennifer L Guida; Tim A Ahles; Daniel Belsky; Judith Campisi; Harvey Jay Cohen; James DeGregori; Rebecca Fuldner; Luigi Ferrucci; Lisa Gallicchio; Leonid Gavrilov; Natalia Gavrilova; Paige A Green; Chamelli Jhappan; Ronald Kohanski; Kevin Krull; Jeanne Mandelblatt; Kirsten K Ness; Ann O'Mara; Nathan Price; Jennifer Schrack; Stephanie Studenski; Olga Theou; Russell P Tracy; Arti Hurria
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

4.  Role of the initial degree of anaemia and treatment model in the prognosis of gastric cancer patients treated by chemotherapy: a retrospective analysis.

Authors:  Wen-Huan Li; Ji-Yu Zhang; Wen-Hui Liu; Xian-Xian Chen
Journal:  BMC Cancer       Date:  2020-05-13       Impact factor: 4.430

5.  Controlling Nutritional Status Score Before Receiving Treatment as a Prognostic Indicator for Patients With Urothelial Cancer: An Exploration Evaluation Methods.

Authors:  Lei Peng; Chunxiao Du; Chunyang Meng; Jinze Li; Chengyu You; Xianhui Li; Pan Zhao; Dehong Cao; Yunxiang Li
Journal:  Front Oncol       Date:  2021-10-13       Impact factor: 6.244

6.  Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.

Authors:  Li Wei; Jie Chen; Jingyun Wen; Donghao Wu; Xiaokun Ma; Zhanhong Chen; Jianglong Huang
Journal:  Med Sci Monit       Date:  2020-02-16

7.  Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy.

Authors:  Xianghua Zeng; Shicong Zhu; Cheng Xu; Zhongyu Wang; Xingxing Su; Dong Zeng; Haixia Long; Bo Zhu
Journal:  Med Sci Monit       Date:  2020-09-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.